Moderna to end mRNA COVID shot production at Lonza plant
JHVEPhoto/iStock Editorial via Getty Images

Moderna (NASDAQ:MRNA) will ramp down production of mRNA drug substance used in its COVID-19 shots at a Lonza (OTCPK:LZAGY) (OTCPK:LZAGF) facility in Switzerland as demand for the jabs has been declining as COVID is no longer a pandemic.
The biotech said it has enough production capacity going forward at facilities in Norwood, Mass., for 2024.

In addition, Moderna (MRNA) will have additional capacity at factories under development in the UK, Canada, and Australia.


More on Moderna

Moderna: Buy Before The Fall Covid-19 Wave
Moderna slips 8% as Pfizer COVID shot forecast weighs on shares
Pfizer sees 24% of eligible Americans getting COVID-19 boosters
Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases
The 'tripledemic' threat to be less severe this season